Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease

Vicente Torres, Jared J. Grantham, Arlene B. Chapman, Michal Mrug, Kyongtae T. Bae, Bernard Francis King, Louis H. Wetzel, Diego Martin, Mark E. Lockhart, William M. Bennett, Marva Moxey-Mims, Kaleab Z. Abebe, Yan Lin, James E. Bost

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Background and objectives: The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) was created to identify markers of disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD). Design, setting, participants, & measurements: Linear mixed models were utilized to model effects of baseline parameters on changes in natural-log (ln)-transformed total kidney volume (TKV) and iothalamate clearance (GFR) across time in CRISP participants (creatinine clearance at entry >70 ml/min). Stepwise selection was used to obtain a final main effect model. Results: TKV increased from year to year, whereas GFR uncorrected for body surface area (BSA) decreased only at year 6. Higher lnTKV and urine sodium excretion (U NaV), lower serum HDL-cholesterol, and younger age at baseline associated with greater lnTKV growth from baseline to year 3 and to year 6. Higher lnTKV at baseline associated with greater GFR decline from year 1 to year 3 and to year 6. Higher BSA and 24-hour urine osmolality at baseline associated with greater GFR decline from year 1 to year 6. Higher UNaV and lower serum HDL-cholesterol at baseline associated with greater GFR decline from year 1 to year 6 by univariate analysis only. Associations seen during year 1 to year 6 (not seen during year 1 to year 3) reflect the time lag between structural and functional disease progression. Conclusions: Serum HDL-cholesterol, UNaV, and 24-hour urine osmolality likely affect ADPKD progression. To what extent their modification may influence the clinical course of ADPKD remains to be determined.

Original languageEnglish (US)
Pages (from-to)640-647
Number of pages8
JournalClinical Journal of the American Society of Nephrology
Volume6
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

Autosomal Dominant Polycystic Kidney
HDL Cholesterol
Disease Progression
Polycystic Kidney Diseases
Body Surface Area
Urine
Osmolar Concentration
Serum
Iothalamic Acid
Kidney
Linear Models
Creatinine
Sodium
Growth

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. / Torres, Vicente; Grantham, Jared J.; Chapman, Arlene B.; Mrug, Michal; Bae, Kyongtae T.; King, Bernard Francis; Wetzel, Louis H.; Martin, Diego; Lockhart, Mark E.; Bennett, William M.; Moxey-Mims, Marva; Abebe, Kaleab Z.; Lin, Yan; Bost, James E.

In: Clinical Journal of the American Society of Nephrology, Vol. 6, No. 3, 01.03.2011, p. 640-647.

Research output: Contribution to journalArticle

Torres, V, Grantham, JJ, Chapman, AB, Mrug, M, Bae, KT, King, BF, Wetzel, LH, Martin, D, Lockhart, ME, Bennett, WM, Moxey-Mims, M, Abebe, KZ, Lin, Y & Bost, JE 2011, 'Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease', Clinical Journal of the American Society of Nephrology, vol. 6, no. 3, pp. 640-647. https://doi.org/10.2215/CJN.03250410
Torres, Vicente ; Grantham, Jared J. ; Chapman, Arlene B. ; Mrug, Michal ; Bae, Kyongtae T. ; King, Bernard Francis ; Wetzel, Louis H. ; Martin, Diego ; Lockhart, Mark E. ; Bennett, William M. ; Moxey-Mims, Marva ; Abebe, Kaleab Z. ; Lin, Yan ; Bost, James E. / Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. In: Clinical Journal of the American Society of Nephrology. 2011 ; Vol. 6, No. 3. pp. 640-647.
@article{731b47c9f4604df289f990a3f831cfe4,
title = "Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease",
abstract = "Background and objectives: The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) was created to identify markers of disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD). Design, setting, participants, & measurements: Linear mixed models were utilized to model effects of baseline parameters on changes in natural-log (ln)-transformed total kidney volume (TKV) and iothalamate clearance (GFR) across time in CRISP participants (creatinine clearance at entry >70 ml/min). Stepwise selection was used to obtain a final main effect model. Results: TKV increased from year to year, whereas GFR uncorrected for body surface area (BSA) decreased only at year 6. Higher lnTKV and urine sodium excretion (U NaV), lower serum HDL-cholesterol, and younger age at baseline associated with greater lnTKV growth from baseline to year 3 and to year 6. Higher lnTKV at baseline associated with greater GFR decline from year 1 to year 3 and to year 6. Higher BSA and 24-hour urine osmolality at baseline associated with greater GFR decline from year 1 to year 6. Higher UNaV and lower serum HDL-cholesterol at baseline associated with greater GFR decline from year 1 to year 6 by univariate analysis only. Associations seen during year 1 to year 6 (not seen during year 1 to year 3) reflect the time lag between structural and functional disease progression. Conclusions: Serum HDL-cholesterol, UNaV, and 24-hour urine osmolality likely affect ADPKD progression. To what extent their modification may influence the clinical course of ADPKD remains to be determined.",
author = "Vicente Torres and Grantham, {Jared J.} and Chapman, {Arlene B.} and Michal Mrug and Bae, {Kyongtae T.} and King, {Bernard Francis} and Wetzel, {Louis H.} and Diego Martin and Lockhart, {Mark E.} and Bennett, {William M.} and Marva Moxey-Mims and Abebe, {Kaleab Z.} and Yan Lin and Bost, {James E.}",
year = "2011",
month = "3",
day = "1",
doi = "10.2215/CJN.03250410",
language = "English (US)",
volume = "6",
pages = "640--647",
journal = "Clinical Journal of the American Society of Nephrology",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "3",

}

TY - JOUR

T1 - Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease

AU - Torres, Vicente

AU - Grantham, Jared J.

AU - Chapman, Arlene B.

AU - Mrug, Michal

AU - Bae, Kyongtae T.

AU - King, Bernard Francis

AU - Wetzel, Louis H.

AU - Martin, Diego

AU - Lockhart, Mark E.

AU - Bennett, William M.

AU - Moxey-Mims, Marva

AU - Abebe, Kaleab Z.

AU - Lin, Yan

AU - Bost, James E.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background and objectives: The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) was created to identify markers of disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD). Design, setting, participants, & measurements: Linear mixed models were utilized to model effects of baseline parameters on changes in natural-log (ln)-transformed total kidney volume (TKV) and iothalamate clearance (GFR) across time in CRISP participants (creatinine clearance at entry >70 ml/min). Stepwise selection was used to obtain a final main effect model. Results: TKV increased from year to year, whereas GFR uncorrected for body surface area (BSA) decreased only at year 6. Higher lnTKV and urine sodium excretion (U NaV), lower serum HDL-cholesterol, and younger age at baseline associated with greater lnTKV growth from baseline to year 3 and to year 6. Higher lnTKV at baseline associated with greater GFR decline from year 1 to year 3 and to year 6. Higher BSA and 24-hour urine osmolality at baseline associated with greater GFR decline from year 1 to year 6. Higher UNaV and lower serum HDL-cholesterol at baseline associated with greater GFR decline from year 1 to year 6 by univariate analysis only. Associations seen during year 1 to year 6 (not seen during year 1 to year 3) reflect the time lag between structural and functional disease progression. Conclusions: Serum HDL-cholesterol, UNaV, and 24-hour urine osmolality likely affect ADPKD progression. To what extent their modification may influence the clinical course of ADPKD remains to be determined.

AB - Background and objectives: The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) was created to identify markers of disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD). Design, setting, participants, & measurements: Linear mixed models were utilized to model effects of baseline parameters on changes in natural-log (ln)-transformed total kidney volume (TKV) and iothalamate clearance (GFR) across time in CRISP participants (creatinine clearance at entry >70 ml/min). Stepwise selection was used to obtain a final main effect model. Results: TKV increased from year to year, whereas GFR uncorrected for body surface area (BSA) decreased only at year 6. Higher lnTKV and urine sodium excretion (U NaV), lower serum HDL-cholesterol, and younger age at baseline associated with greater lnTKV growth from baseline to year 3 and to year 6. Higher lnTKV at baseline associated with greater GFR decline from year 1 to year 3 and to year 6. Higher BSA and 24-hour urine osmolality at baseline associated with greater GFR decline from year 1 to year 6. Higher UNaV and lower serum HDL-cholesterol at baseline associated with greater GFR decline from year 1 to year 6 by univariate analysis only. Associations seen during year 1 to year 6 (not seen during year 1 to year 3) reflect the time lag between structural and functional disease progression. Conclusions: Serum HDL-cholesterol, UNaV, and 24-hour urine osmolality likely affect ADPKD progression. To what extent their modification may influence the clinical course of ADPKD remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=79953011165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953011165&partnerID=8YFLogxK

U2 - 10.2215/CJN.03250410

DO - 10.2215/CJN.03250410

M3 - Article

VL - 6

SP - 640

EP - 647

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

SN - 1555-9041

IS - 3

ER -